Previous clinical studies from Affimed GmbH assessing AFM13 safety and tolerability in patients with Hodgkin lymphoma demonstrated activation of NK cells and a reduction in CD30 levels in peripheral blood samples [clinicaltrials.gov ID: NCT01221571]. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.